Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Diabetes Care Publish Ahead of Print published online ahead of print February 5, 2008
DOI: 10.2337/dc07-1967

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dc07-1967v1
31/5/934    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Weinzimer, S. A
Right arrow Articles by Tamborlane, W. V
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weinzimer, S. A
Right arrow Articles by Tamborlane, W. V
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Original Research

Fully Automated Closed-Loop Insulin Delivery vs. Semi-Automated Hybrid Control in Pediatric Patients with Type 1 Diabetes using an Artificial Pancreas

Stuart A Weinzimer, MD1, Garry M Steil, MD3, Karena L Swan, MD1, Jim Dziura, MD2, Natalie Kurtz, MD3 and William V Tamborlane, MD1,,2

1Department of Pediatrics and
2Yale Center for Clinical Investigation, Yale University School of Medicine, New Haven, CT; and
3Medtronic MiniMed, Northridge, CA

stuart.weinzimer{at}yale.edu

ABSTRACT

Objective: The most promising beta-cell replacement therapy for children with type 1 diabetes is a "closed-loop" (CL) artificial pancreas incorporating continuous glucose sensors and insulin pumps. The Medtronic MiniMed ePID System combines an external pump and sensor with a variable insulin infusion rate algorithm designed to emulate the physiological characteristics of the β-cell. However, delays in insulin absorption associated with subcutaneous route of delivery inevitably lead to large post-prandial glucose excursions.

Research Design and Methods: We studied the feasibility of the Medtronic ePID system in youth with type 1 diabetes and hypothesized that small manual pre-meal "priming" boluses would reduce post-prandial excursions during CL control. 17 adolescents (age 15.9± 1.6 y, A1c 7.1± 0.8%) underwent 34 hours of closed-loop (CL) control; 8 with full CL control (FCL), and 9 with "hybrid" CL (pre-meal priming bolus, HCL).

Results: Mean glucose levels were 135± 45 mg/dL in the HCL group vs. 141± 55 mg/dL in the FCL group (p=0.09); day-time glucose levels averaged 149± 47 mg/dL in the HCL group vs. 159± 59 mg/dL in the FCL group (p=0.03). Peak post-prandial glucose levels averaged 194± 47 mg/dL in the HCL group, vs. 226± 51 mg/dL in the FCL group (p=0.04). Night-time control was similar in both groups (111± 27 vs. 112± 28 mg/dL).

Conclusions: CL glucose control using an external sensor and insulin pump provides a means to achieve near normal glucose concentrations in youth with type 1 diabetes during the overnight period. The addition of small manual "priming" bolus doses of insulin, given 15 min before meals, improves post-prandial glycemic excursions.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2008 by the American Diabetes Association.